ArticleCell death & disease2026
A Lamp2a-linked RNA secreted by ADSCs prevents ENO1-lactylation-glycolysis feedback and cell malignant behavior in triple-negative breast cancer.
Article in Cell death & disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- ENO1 as a Central Regulator Linking Metabolic Reprogramming to Tumor Plasticity.International journal of molecular sciences · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Triple-negative breast cancer (TNBC) is a subtype characterized by the absence of common BC receptors and is closely associated with a hypoxic tumor microenvironment. However, the mechanisms through which TNBCs adapt to hypoxia remain elusive. This study revealed elevated ENO1 levels in various BC datasets and revealed ENO1 protein lactylation in BC samples through 4D label-free lactylation quantitative proteomics analysis. The results indicated that lactylation increases ENO1 protein stability and enzyme activity, which promotes glycolysis. Notably, as lactate levels increased, a positive feedback loop was established, further promoting lactylation of ENO1. This positive feedback mechanism enables TNBC cells to adapt more efficiently to hypoxia and enhances their malignant behaviors. Lactylation prevented the lysosomal degradation of ENO1. In this study, the characteristics of ENO1, an RNA-binding protein, were assessed to determine how to interfere with its lactylation; specifically, an RNA ligand that can be specifically bound by ENO1 was identified. The RNA ligand was found to be linked to the Lamp2a protein in adipose stem cells (ADSCs) after stable transfection with Lamp2a-TAT and TRA-ligand plasmids. ADSCs seeded in a polyglycolic acid scaffold secreted exosomes containing the Lamp2a-linked ligand. This RNA ligand binds to ENO1 after it enters TNBC cells and further induces the lysosomal degradation of ENO1 by the Lamp2a protein. Consequently, glycolysis, which is associated with malignant cell behaviors, is inhibited. Overall, this study elucidated the role of ENO1 lactylation-mediated glycolysis in TNBC adaptation to hypoxia and provides a strategy for targeting ENO1.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.